French Industry Rages Over €1.7bn Drug Savings Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
Measure includes €550bn in drug price cuts.
You may also be interested in...
France 2017: More Price Cuts, Rebates, Generics and Biosimilars, And A New Innovation Fund
The French pharmaceutical industry has reacted angrily to some of the provisions in the 2017 social security financing bill, arguing that the measures are inappropriate and that the government is taking a purely financial approach to addressing the costs of healthcare products, rather than taking wider public health considerations into account.
France 2017: More Price Cuts, Rebates, Generics and Biosimilars, And A New Innovation Fund
The French pharmaceutical industry has reacted angrily to some of the provisions in the 2017 social security financing bill, arguing that the measures are inappropriate and that the government is taking a purely financial approach to addressing the costs of healthcare products, rather than taking wider public health considerations into account.
European Notebook: Pricing Mistrust Needs Open Debate; Rasi Nears EMA Return; Market Turmoil Affects IPOs
The EU’s Health Commissioner called for an open debate on pharmaceutical pricing with industry, while Guido Rasi prepares for part two of helming the European Medicines Agency and German big pharmas Bayer and Merck KGaA completed business restructuring. More developments in this month's column.